PubMed:32243945 JSONTXT

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":89},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":90,"end":299},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":300,"end":429},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":430,"end":682},"obj":"Sentence"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok1","span":{"begin":0,"end":9},"obj":"NNP"},{"id":"tok2","span":{"begin":10,"end":14},"obj":"IN"},{"id":"tok3","span":{"begin":15,"end":27},"obj":"NN"},{"id":"tok4","span":{"begin":28,"end":34},"obj":"NN"},{"id":"tok5","span":{"begin":35,"end":38},"obj":"IN"},{"id":"tok6","span":{"begin":39,"end":49},"obj":"RB"},{"id":"tok7","span":{"begin":50,"end":53},"obj":"JJ"},{"id":"tok8","span":{"begin":54,"end":62},"obj":"NNS"},{"id":"tok9","span":{"begin":63,"end":67},"obj":"IN"},{"id":"tok10","span":{"begin":68,"end":77},"obj":"NNP"},{"id":"tok11","span":{"begin":77,"end":78},"obj":"CD"},{"id":"tok12","span":{"begin":79,"end":88},"obj":"NN"},{"id":"tok13","span":{"begin":88,"end":89},"obj":"."},{"id":"tok14","span":{"begin":90,"end":92},"obj":"IN"},{"id":"tok15","span":{"begin":93,"end":95},"obj":"IN"},{"id":"tok16","span":{"begin":96,"end":101},"obj":"NNP"},{"id":"tok17","span":{"begin":102,"end":104},"obj":"CD"},{"id":"tok18","span":{"begin":104,"end":105},"obj":","},{"id":"tok19","span":{"begin":106,"end":110},"obj":"CD"},{"id":"tok20","span":{"begin":110,"end":111},"obj":","},{"id":"tok21","span":{"begin":112,"end":117},"obj":"JJ"},{"id":"tok22","span":{"begin":118,"end":124},"obj":"JJ"},{"id":"tok23","span":{"begin":125,"end":130},"obj":"JJ"},{"id":"tok24","span":{"begin":131,"end":142},"obj":"JJ"},{"id":"tok25","span":{"begin":143,"end":151},"obj":"NN"},{"id":"tok26","span":{"begin":152,"end":163},"obj":"JJ"},{"id":"tok27","span":{"begin":164,"end":165},"obj":"CD"},{"id":"tok28","span":{"begin":166,"end":167},"obj":"("},{"id":"tok29","span":{"begin":167,"end":176},"obj":"NNP"},{"id":"tok30","span":{"begin":176,"end":177},"obj":"LS"},{"id":"tok31","span":{"begin":177,"end":178},"obj":")"},{"id":"tok32","span":{"begin":179,"end":182},"obj":"VBZ"},{"id":"tok33","span":{"begin":183,"end":187},"obj":"VBN"},{"id":"tok34","span":{"begin":188,"end":199},"obj":"JJ"},{"id":"tok35","span":{"begin":200,"end":203},"obj":"IN"},{"id":"tok36","span":{"begin":204,"end":207},"obj":"CD"},{"id":"tok37","span":{"begin":207,"end":208},"obj":","},{"id":"tok38","span":{"begin":208,"end":211},"obj":"CD"},{"id":"tok39","span":{"begin":212,"end":221},"obj":"NN"},{"id":"tok40","span":{"begin":222,"end":227},"obj":"NNS"},{"id":"tok41","span":{"begin":228,"end":232},"obj":"IN"},{"id":"tok42","span":{"begin":233,"end":235},"obj":"CD"},{"id":"tok43","span":{"begin":235,"end":236},"obj":","},{"id":"tok44","span":{"begin":236,"end":239},"obj":"CD"},{"id":"tok45","span":{"begin":240,"end":246},"obj":"NNS"},{"id":"tok46","span":{"begin":247,"end":255},"obj":"RB"},{"id":"tok47","span":{"begin":256,"end":259},"obj":"CC"},{"id":"tok48","span":{"begin":260,"end":263},"obj":"DT"},{"id":"tok49","span":{"begin":264,"end":270},"obj":"NN"},{"id":"tok50","span":{"begin":271,"end":273},"obj":"VBZ"},{"id":"tok51","span":{"begin":274,"end":279},"obj":"RB"},{"id":"tok52","span":{"begin":280,"end":290},"obj":"VBG"},{"id":"tok53","span":{"begin":291,"end":298},"obj":"RB"},{"id":"tok54","span":{"begin":298,"end":299},"obj":"."},{"id":"tok55","span":{"begin":300,"end":306},"obj":"NNP"},{"id":"tok56","span":{"begin":306,"end":307},"obj":","},{"id":"tok57","span":{"begin":308,"end":310},"obj":"PRP"},{"id":"tok58","span":{"begin":311,"end":320},"obj":"VBD"},{"id":"tok59","span":{"begin":321,"end":325},"obj":"CD"},{"id":"tok60","span":{"begin":326,"end":336},"obj":"RB"},{"id":"tok61","span":{"begin":337,"end":340},"obj":"JJ"},{"id":"tok62","span":{"begin":341,"end":349},"obj":"NNS"},{"id":"tok63","span":{"begin":350,"end":354},"obj":"IN"},{"id":"tok64","span":{"begin":355,"end":364},"obj":"NNP"},{"id":"tok65","span":{"begin":364,"end":365},"obj":"CD"},{"id":"tok66","span":{"begin":366,"end":375},"obj":"NN"},{"id":"tok67","span":{"begin":376,"end":379},"obj":"WP"},{"id":"tok68","span":{"begin":380,"end":388},"obj":"VBD"},{"id":"tok69","span":{"begin":389,"end":399},"obj":"JJ"},{"id":"tok70","span":{"begin":400,"end":404},"obj":"NN"},{"id":"tok71","span":{"begin":405,"end":408},"obj":"CC"},{"id":"tok72","span":{"begin":409,"end":421},"obj":"NN"},{"id":"tok73","span":{"begin":422,"end":428},"obj":"NN"},{"id":"tok74","span":{"begin":428,"end":429},"obj":"."},{"id":"tok75","span":{"begin":430,"end":438},"obj":"IN"},{"id":"tok76","span":{"begin":439,"end":442},"obj":"PDT"},{"id":"tok77","span":{"begin":443,"end":446},"obj":"DT"},{"id":"tok78","span":{"begin":447,"end":451},"obj":"CD"},{"id":"tok79","span":{"begin":452,"end":460},"obj":"NNS"},{"id":"tok80","span":{"begin":461,"end":462},"obj":"("},{"id":"tok81","span":{"begin":462,"end":471},"obj":"VBG"},{"id":"tok82","span":{"begin":472,"end":473},"obj":"DT"},{"id":"tok83","span":{"begin":474,"end":482},"obj":"JJ"},{"id":"tok84","span":{"begin":483,"end":488},"obj":"NN"},{"id":"tok85","span":{"begin":488,"end":489},"obj":")"},{"id":"tok86","span":{"begin":490,"end":499},"obj":"VBD"},{"id":"tok87","span":{"begin":500,"end":504},"obj":"IN"},{"id":"tok88","span":{"begin":505,"end":514},"obj":"NNP"},{"id":"tok89","span":{"begin":514,"end":515},"obj":"CD"},{"id":"tok90","span":{"begin":516,"end":525},"obj":"NN"},{"id":"tok91","span":{"begin":526,"end":536},"obj":"RB"},{"id":"tok92","span":{"begin":536,"end":537},"obj":","},{"id":"tok93","span":{"begin":538,"end":548},"obj":"JJ"},{"id":"tok94","span":{"begin":549,"end":555},"obj":"NNS"},{"id":"tok95","span":{"begin":556,"end":559},"obj":"VBP"},{"id":"tok96","span":{"begin":560,"end":566},"obj":"VBN"},{"id":"tok97","span":{"begin":567,"end":569},"obj":"TO"},{"id":"tok98","span":{"begin":570,"end":579},"obj":"VB"},{"id":"tok99","span":{"begin":580,"end":583},"obj":"DT"},{"id":"tok100","span":{"begin":584,"end":590},"obj":"NN"},{"id":"tok101","span":{"begin":591,"end":593},"obj":"IN"},{"id":"tok102","span":{"begin":594,"end":599},"obj":"JJ"},{"id":"tok103","span":{"begin":600,"end":610},"obj":"NNS"},{"id":"tok104","span":{"begin":611,"end":614},"obj":"CC"},{"id":"tok105","span":{"begin":615,"end":626},"obj":"VB"},{"id":"tok106","span":{"begin":627,"end":630},"obj":"DT"},{"id":"tok107","span":{"begin":631,"end":637},"obj":"NN"},{"id":"tok108","span":{"begin":638,"end":641},"obj":"CC"},{"id":"tok109","span":{"begin":642,"end":650},"obj":"NN"},{"id":"tok110","span":{"begin":651,"end":653},"obj":"IN"},{"id":"tok111","span":{"begin":654,"end":666},"obj":"NN"},{"id":"tok112","span":{"begin":667,"end":673},"obj":"NN"},{"id":"tok113","span":{"begin":674,"end":681},"obj":"NN"},{"id":"tok114","span":{"begin":681,"end":682},"obj":"."},{"id":"lookup1","span":{"begin":96,"end":101},"obj":"location"},{"id":"lookup2","span":{"begin":96,"end":101},"obj":"date"},{"id":"lookup3","span":{"begin":106,"end":110},"obj":"year"},{"id":"lookup4","span":{"begin":271,"end":273},"obj":"country_code"},{"id":"lookup5","span":{"begin":321,"end":325},"obj":"time"},{"id":"lookup6","span":{"begin":321,"end":325},"obj":"number"},{"id":"lookup7","span":{"begin":447,"end":451},"obj":"time"},{"id":"lookup8","span":{"begin":447,"end":451},"obj":"number"},{"id":"lookup9","span":{"begin":567,"end":569},"obj":"country_code"},{"id":"event1","span":{"begin":490,"end":499},"obj":"OCCURRENCE"},{"id":"event2","span":{"begin":280,"end":290},"obj":"OCCURRENCE"},{"id":"event3","span":{"begin":570,"end":579},"obj":"OCCURRENCE"},{"id":"event4","span":{"begin":311,"end":320},"obj":"REPORTING"},{"id":"event5","span":{"begin":615,"end":626},"obj":"I_ACTION"},{"id":"event6","span":{"begin":380,"end":388},"obj":"OCCURRENCE"},{"id":"event7","span":{"begin":560,"end":566},"obj":"I_STATE"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T1","span":{"begin":68,"end":76},"obj":"Disease"},{"id":"T2","span":{"begin":79,"end":88},"obj":"Disease"},{"id":"T3","span":{"begin":118,"end":165},"obj":"Disease"},{"id":"T4","span":{"begin":118,"end":151},"obj":"Disease"},{"id":"T5","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T6","span":{"begin":212,"end":221},"obj":"Disease"},{"id":"T7","span":{"begin":355,"end":363},"obj":"Disease"},{"id":"T8","span":{"begin":366,"end":375},"obj":"Disease"},{"id":"T9","span":{"begin":505,"end":513},"obj":"Disease"},{"id":"T10","span":{"begin":516,"end":525},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T1","span":{"begin":28,"end":34},"obj":"Body_part"},{"id":"T2","span":{"begin":422,"end":428},"obj":"Body_part"},{"id":"T3","span":{"begin":667,"end":673},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":28,"end":34},"obj":"UBERON:0001969"},{"id":"T2","span":{"begin":68,"end":78},"obj":"SP_7"},{"id":"T3","span":{"begin":118,"end":165},"obj":"SP_7"},{"id":"T4","span":{"begin":131,"end":142},"obj":"UBERON:0001004"},{"id":"T5","span":{"begin":167,"end":177},"obj":"SP_7"},{"id":"T6","span":{"begin":240,"end":246},"obj":"GO:0016265"},{"id":"T7","span":{"begin":355,"end":365},"obj":"SP_7"},{"id":"T8","span":{"begin":422,"end":428},"obj":"UBERON:0001969"},{"id":"T9","span":{"begin":474,"end":482},"obj":"GO:0007565"},{"id":"T10","span":{"begin":505,"end":515},"obj":"SP_7"},{"id":"T11","span":{"begin":667,"end":673},"obj":"UBERON:0001969"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}

{"project":"MeasurableQuantitativeAnnotation","denotations":[{"id":"E1","span":{"begin":212,"end":221},"obj":"entity"},{"id":"E2","span":{"begin":240,"end":246},"obj":"entity"},{"id":"N1","span":{"begin":204,"end":211},"obj":"num"},{"id":"N2","span":{"begin":233,"end":239},"obj":"num"},{"id":"U1","span":{"begin":222,"end":227},"obj":"unit"}],"relations":[{"id":"R1","pred":"associateWith","subj":"E1","obj":"N1"},{"id":"R2","pred":"associateOf","subj":"N1","obj":"U1"},{"id":"R3","pred":"associateWith","subj":"E2","obj":"N2"}],"text":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.\nAs of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally and the number is still increasing rapidly. Herein, we presented four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all the four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy."}